Siemens Healthineers, Mayo Clinic Partner on Neurodegenerative Disease, Cancer

Why It Matters

By merging AI with advanced imaging, the partnership promises earlier, more accurate diagnoses and personalized therapies, potentially reshaping standards in oncology and neurology while driving growth in the high‑value medical‑technology market.

Key Takeaways

• AI‑enhanced MRI targets Alzheimer’s early detection
• AI aims to cut prostate biopsies
• Image‑guided tech improves liver metastasis treatment
• Whole‑body PET/CT integrated for cancer planning
• Collaboration also tackles hospital air quality

Pulse Analysis

The alliance between Siemens Healthineers and the Mayo Clinic marks a decisive step in the convergence of artificial intelligence and next‑generation imaging. Both organizations have a track record of pioneering diagnostic tools, and their renewed agreement expands beyond earlier joint projects with GE HealthCare. By pooling Siemens’ hardware expertise—ultra‑high‑field MRI, PET/CT, and low‑dose CT—with Mayo’s clinical research infrastructure, the partnership aims to fast‑track technologies from the lab to bedside. In a market where AI‑driven radiology solutions are projected to exceed $10 billion by 2030, this collaboration positions both firms at the forefront of a rapidly commercializing segment.

In the neurodegenerative arena, the focus is on AI‑enabled magnetic resonance protocols that can detect subtle brain atrophy patterns associated with Alzheimer’s and other dementias. Ultra‑high‑field scanners provide unprecedented spatial resolution, while machine‑learning algorithms automate volumetric analysis, reducing inter‑reader variability. Earlier, more reliable diagnoses could shift patients into therapeutic trials sooner, potentially altering disease trajectories. Moreover, the initiative includes longitudinal monitoring tools, allowing clinicians to track disease progression with quantitative biomarkers, a capability that has been largely absent from routine practice.

The oncology component tackles prostate cancer biopsy reduction and precise treatment of metastatic liver tumors. AI models trained on multi‑modal imaging data promise to identify clinically significant lesions, sparing patients unnecessary invasive procedures. Integrated whole‑body PET/CT and advanced MR imaging will support personalized treatment planning, aligning with the broader industry move toward value‑based care. Additional work on surgical workflow optimization and hospital air‑quality improvement reflects a holistic view of patient outcomes. If successful, these advances could set new standards for imaging‑guided therapy across major health systems.

Siemens Healthineers, Mayo Clinic partner on neurodegenerative disease, cancer

By Susan Kelly, Reporter · Published Feb. 13, 2026

Siemens Healthineers’ headquarters in Erlangen, Germany. Siemens Healthineers will work with the Mayo Clinic on technologies to improve diagnosis and treatment in three areas of disease. Courtesy of Siemens Healthineers

Siemens Healthineers and Mayo Clinic will expand a strategic collaboration aimed at improving diagnosis and treatment of neurodegenerative disease and cancer through new imaging and interventional technologies.

The partners said Thursday they signed an agreement that covers management of prostate cancer and metastatic liver tumors, in addition to neurodegenerative disease.

Eric Williamson, chair of diagnostic radiology at Mayo Clinic, said the effort aims to bring advanced imaging, artificial intelligence and new treatment approaches into everyday care, potentially enabling earlier diagnoses and more personalized treatment plans.

“Our goal is to make care more precise, less invasive, and more responsive to each patient’s needs,” Williamson said in a statement.

In neurodegenerative disease, the collaboration includes work on AI‑enabled magnetic resonance imaging protocols for improved diagnostic accuracy and patient monitoring. A focus will be clinical adoption and translation of ultra‑high‑field MRI protocols, which have high resolution and enhanced contrast for diagnostic and surgical planning that can aid in complex neurological disease states. Imaging tests are typically used to help diagnose Alzheimer’s disease, where an MRI can show a pattern of shrinkage in the brain.

For prostate cancer, the role of AI in minimizing biopsies will be investigated, along with integration of advanced imaging into diagnostic and therapeutic procedures. In liver cancer, efforts will focus on clinical translation of image‑guided technologies for precise detection and treatment of metastases.

Other areas of collaboration include work to improve the patient surgical experience and operational efficiency, and integration of whole‑body PET/CT in treatment for certain cancers and anatomical and metabolic MR imaging in diagnostic and therapeutic planning.

Mayo Clinic’s partnerships with imaging companies include a 2023 collaboration with GE HealthCare on radiology research. The two organizations announced an initiative late last year to integrate imaging, AI and patient monitoring to improve cancer care through personalized therapy.

Siemens Healthineers and Mayo are also working together on a project to improve hospital air quality and previously collaborated on technology to reduce radiation exposure from CT scanners.